Signaling through Free Fatty Acid Receptor 4 Attenuates Cardiometabolic Disease

  • Physiology (Bethesda). 2022 Nov 1;37(6):311-322. doi: 10.1152/physiol.00007.2022.
Timothy D O'Connell  1 ,  Katherine A Murphy  1 ,  Naixin Zhang  1 ,  Sara J Puccini  1 ,  Chastity L Healy  1 ,  Brian A Harsch  2 ,  Michael J Zhang  1 ,  Gregory C Shearer  2
Affiliations
  • 1. Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota.
  • 2. Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania.
PMID: 35944007 DOI: 10.1152/physiol.00007.2022
Abstract

A surge in the prevalence of obesity and metabolic syndrome, which promote systemic inflammation, underlies an increase in cardiometabolic disease. Free Fatty Acid Receptor 4 is a nutrient sensor for long-chain fatty acids, like ω3-polyunsaturated fatty acids (ω3-PUFAs), that attenuates Metabolic Disease and resolves inflammation. Clinical trials indicate ω3-PUFAs are cardioprotective, and this review discusses the mechanistic links between ω3-PUFAs, Free Fatty Acid Receptor 4, and attenuation of cardiometabolic disease.

Keywords
18-hydroxyeicosapentaenoic acid (18-HEPE); cardiometabolic disease; free fatty acid receptor 4 (Ffar4); heart; specialized proresolving mediators (SPM); ω3-polyunsaturated fatty acids (ω3-PUFAs).